United Kingdom: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in United Kingdom

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: United Kingdom: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Subscribe to access the full database, or Subscribe
Tradename	Ingredient	Estimated Entry Opportunity Date
PICATO	ingenol mebutate	2025-12-16
APTIOM	eslicarbazepine acetate	2025-07-29
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: United Kingdom: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

When can PICATO (ingenol mebutate) generic drug versions launch?

Generic name: ingenol mebutate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: United Kingdom Patent 525,680

PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.

When can APTIOM (eslicarbazepine acetate) generic drug versions launch?

Generic name: eslicarbazepine acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: United Kingdom Patent 515,690

APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Generic Entry Dates in Other Countries

Details: United Kingdom: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Make Better Decisions: Try a trial or see plans & pricing